Luminal A Breast Adenocarcinoma Has Similar Rate of Metastatic Progression as Luminal B but Greater Overall and Disease Free Survival.
Riyam Zreik, Cary Chisholm, Courtney Yao, Christopher Ruud, VO Speights. Scott & White Memorial Hospital, Temple, TX
Background: Breast cancer has been classified into subtypes based on type of differentiation (ductal, lobular, etc) and/or immunohistochemical and fluorescence in-situ hybridization characteristics (Luminal A, Luminal B, etc). We studied patients who were found to have metastases at the time of their initial breast cancer diagnosis to evaluate overall/disease free survival and sites of metastases based on their biochemical phenotype.
Design: 108 patients with metastatic breast carcinoma at presentation were identified from 1999-2007. These were sub-typed into Luminal A (ER+/Her2-, Ki-67 <14%), Luminal B (ER+/Her2-, Ki-67 >14%), ER+/Her2+, ER-/Her2+, and triple negative (ER-/PR-/Her2-). Data was compiled regarding the histological criteria of the primary tumor, the sites of metastasis, and overall/disease free survival.
|Variable||Luminal A (N=18)||Luminal B (N=34)||ER+/Her2+ (N=21)||ER-/Her2+ (N=10)||Triple Negative (N=25)|
|Disease Free (months)||55||37||36||35||37|
|Initial Site of Metastasis|
|Site of Metastasis Progression|